Despite efforts to manage HTN through medication and lifestyle changes, over half of those with high blood pressure fail to meet treatment goals. Medical therapy is hindered by issues like cost, side effects, access limitations, and adherence problems. RDN offers a minimally invasive solution by targeting nerves near the renal arteries. Clinical trials reveal that disrupting these nerves reduces blood pressure safely in the short term, with evidence suggesting lasting effects.

In 2021, SCAI and the National Kidney Foundation jointly published an expert consensus statement, which discusses HTN control history, trial data, multidisciplinary assessments, and patient-centered decisions for potential RDN candidates.

This 2023 SCAI statement aims to standardize protocols and enhance procedural outcomes, and covers patient selection, procedural insights, operator training, and institutional requirements for successful implementation.

All authors: Rajesh V. Swaminathan, MD, FSCAI; Cara Anne East, MD, Dmitriy N. Feldman, MD, FSCAI; Naomi D. Fisher, MD; Joseph M. Garasic, MD, FSCAI; Jay S. Giri, MD, MPH, FSCAI; David E. Kandzari, MD, FSCAI; Ajay J. Kirtane, MD, SM, FSCAI; Andrew Klein, MD, FSCAI; Taisei Kobayashi, MD, FSCAI; Gerald Koenig, MD, FSCAI; Jun Li, MD, FSCAI; Eric Secemsky, MD, MSc, FSCAI; Raymond R. Townsend, MD; and Herbert D. Aronow, MD, MPH, FSCAI